The FDA has approved Navidea Biopharmaceuticals' radioactive tracer Lymphoseek for breast cancer and melanoma intraoperative lymphatic mapping. The FDA said the tracer is the first agent for lymph node mapping to gain approval in more than three decades. "Removal and pathologic examination of lymph nodes draining a primary tumor is an important diagnostic evaluation for some patients with breast cancer or melanoma," said Dr. Shaw Chen of the FDA Center for Drug Evaluation and Research.
FDA approves Lymphoseek for lymph node mapping
SmartBrief Job Listings for Health Care
|Sr. Medical Device Reimbursement Specialist - Regional||
|Fort Worth , TX|
|Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group||
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST||
Matheson Tri-Gas, Inc.
ASAHI INTECC, Orange County CA R&D Center
|Santa Ana, CA|